Bayer sues India over Nexavar compulsory license; U.K. shingles vaccine program stalls on Zostavax constraints;

@FiercePharma: ICYMI: Top 10 Drugmakers in Emerging Markets. Special report | Follow @FiercePharma

@EricPFierce: Big forecasts for biologics like Kadcyla lead Roche to invest $900 million in biologics production. Article | Follow @EricPFierce

@CarlyHFierce: FiercePharma gets a shoutout in The New York Times (as a source for this asthma piece). | Follow @CarlyHFierce

> Bayer HealthCare has challenged India's compulsory license on Nexavar with a suit filed in Bombay High Court. Report

> Nicotine patch-maker LTS Lohmann has attracted buyout offers valuing the company at €1.1 billion to €1.3 billion, or up to $1.8 billion. Report

> As the U.K. rolls out a nationwide shingles vaccination program, officials have capped the size of orders, citing constrained supplies of Merck's ($MRK) shot, Zostavax. Report

> India's Wockhardt lost a certificate entitling it to export drugs to the U.K. after U.S. regulators cut off the same factory because of manufacturing violations. Report

> The U.S. is running out of coral snake antivenin years after Wyeth Pharmaceuticals discontinued manufacturing because of low demand and profit margins, and no one has yet stepped into the breach. Report

> Parsippany, NJ-based Actavis ($ACT) has donated medicines and supplies to refugees in Bulgaria's Elhovo. Report

> Execution drugs mixed by U.S. compounding pharmacies have drawn protests from death-row inmates, and the state of Missouri abandoned a plan to use propofol in an execution after its maker, Fresenius Kabi, protested. Report

Medical Device News

@FierceMedDev: CardioKinetix heart failure treatment device reaches China. More | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical snatches up a company and gets a leadless pacemaker (and possible market edge) in the process. Release | Follow @MarkHFierce

@MichaelGFierce: Gov't shutdown halts FCC's wireless med tech certification. ICYMI Friday | Follow @MichaelGFierce

> Biotronik kicks off absorbable stent trial as market crowds. Article

> CardioDx to hit public markets with planned $86.2M IPO. Report

> Natera expands prenatal test amid global push. News

Biotech News

@FierceBiotech: Parexel looks to Japan for  growth. Story from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Merck KGaA scouts for deep-pocketed partners to leverage its R&D budget. Article | Follow @JohnCFierce

@DamianFierce: While "porcine whipworm" rolls off the tongue, it doesn't seem to do much for Crohn's. Story | Follow @DamianFierce

> In a big shift, analyst takes a skeptical stance on Merck's R&D prospects. Story

> Eli Lilly gambling up to $86M on China cancer drug development deal. News

> Vital Therapies plots $86M IPO as biotech market boils. Report

CRO News

> Quintiles snags registry deal with Muscular Dystrophy Association. Report

> U.K. CRO Cmed expands its U.S. foothold. Item

> Yale partners up to run medical device trials. More

> Icon deepens adaptive trial work with patient-safety service. Story

> Catalent buys up Brazilian CMO with eye on growing market. Article

Biotech IT News

> EDC tops poll of R&D productivity technologies. Article

> From Hollywood to healthcare: How 3-D modeling is shaping drug development. More

> Sanger Institute taps DDN to help with Big Data boom. Article

> Venter outlines plan to print vaccines on Mars. Item

> New details on brains and budget behind Google's Calico emerge. Story

And Finally... The case of cyanide-laced Tylenol that killed 7 people in 1982 remains unsolved. Report (sub. req.)

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.